Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity
Imaging shows drug uptake across multiple tumor types
Enrollment in multi-dosing cohorts continues
Fusion also reported preclinical data showing the combination of FPI-1434 with olaparib resulting in synergistic efficacy against colorectal and lung cancer xenografts, and combination with immune checkpoint inhibitors demonstrated enhanced efficacy in colorectal cancer models
Data featured in oral sessions and posters at the SNMMI 2021 Virtual Annual Meeting
https://finance.yahoo.com/news/fusion-pharmaceuticals-announces-preliminary-safety-201000673.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.